Pharmassist Ltd is a fast-growing, full-service Contract Research Organisation located in Athens, Greece, London, United Kingdom and Nicosia, Cyprus. It operates in Europe since 1999 providing services in Clinical Trials, Pharmacovigilance, Regulatory Affairs, Medical Affairs, Quality Management and has been certified according to ISO 9001, ISO 13485 & ISO 27001 requirements.
The company has been actively participating in R&D projects of basic research with the aim to develop and invest in innovative new health technology.
In 2014, Pharmassist R&D Department begins its operations, and in collaboration with the ACTC Lab of the National and Kapodistrian University of Athens along with pronounced University Oncological Clinical Centers, Pharmassist ventures in the development and commercialization of CE-IVD molecular diagnostic kits in the oncology field.
Pharmassist has been granted 8 patents in the major market areas, based on the methodologies for detecting PIK3CA hotspot mutations and determining the PD-L1 gene expression, respectively.
The European Union and Greek national funds have co-financed part of the research on the above methodologies (CANCER blood scan project).